Article Figures & Data
Figures
- Figure 1.
Characterization of trastuzumab-resistant (HR) cell lines. A, Both parental and HR cell lines were treated with increasing concentrations of trastuzumab for 72 hours. Cell viability was measured by MTT assays. *, P < 0.05. B, Changes in basal expression levels of molecules involved in signaling pathways of HR cell lines compared with parental cell lines.
- Figure 2.
Src inhibitor downregulates the related signaling pathway. Both parental and HR cell lines were treated with bosutinib (0.01, 0.1, and 1 μmol/L) for 24 hours. Src-related signaling pathway molecules were then analyzed.
- Figure 3.
Bosutinib influences the cell cycle. After treatment with bosutinib (0.01, 0.1, and 1 μmol/L) for 48 and 72 hours, cell-cycle analysis was conducted. Data represent three independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
- Figure 4.
Bosutinib inhibits migration of HR cell lines more potently compared with parental cell lines. All cell lines were treated with the indicated concentrations of bosutinib for 48 hours. Images were analyzed by ImageJ software. *, P < 0.05; **P < 0.01; ***, P < 0.001.
- Figure 5.
Inhibition of in vivo tumor growth by bosutinib in SNU2670 and SNU2670HR xenografts. SNU2670 and SNU2670HR cells (2 × 107) were injected into mice, followed by treatment with 150 mg/kg bosutinib for 21 days. A, Changes in mouse body weights during treatment. B, Tumor growth curves of control (vehicle) and bosutinib groups. *, P < 0.05; **, P < 0.01; ***, P < 0.001. Arrow indicates P < 0.05 comparing SNU2670-bosutinib and SNU2670HR-bosutinib treatment groups. C, Tumors were harvested, and then hematoxylin–eosin staining (400×) and IHC analysis (400×) were conducted. D, Proteins were harvested from isolated tumors for Western blotting.
Tables
- Table 1.
IC50 by MTT assay and colony formation assay of bosutinib treatment
IC50 (μmol/L) Cell lines MTT CFA SNU216 2.6 >10 SNU216HR >10 0.69 SNU2773 >10 0.05 SNU2773HR >10 0.31 NCI-N87 >10 >10 NCI-N87HR 4.7 1.1 SNU2670 >10 0.26 SNU2670HR 0.47 0.15
Supplementary Data
- Supplementary Figure - S1- basal expression level S2- MTT Assay and Colony Forming Assay S3- Combination data S4- Trastuzumab monotherapy in vivo
Volume 16, Issue 6
